Trade Summary

1 year ago, Patel Naimish, serving as Chief Medical Officer at Crispr Therapeutics AG (CRSP), purchased 1,508 shares at $32.96 per share, for a total transaction value of $49,704.00. Following this transaction, Patel Naimish now holds 1,508 shares of CRSP.

The trade was executed on Thursday, April 3, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, January 27, 2026 at 5:35 PM ET, 299 days after the trade was made.

Crispr Therapeutics AG operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.